Voveran: Targeted Pain Relief and Inflammation Control
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.42 | $37.84 (0%) | 🛒 Add to cart |
| 120 | $0.40 | $50.45 $48.16 (5%) | 🛒 Add to cart |
| 180 | $0.38 | $75.68 $67.94 (10%) | 🛒 Add to cart |
| 270 | $0.36 | $113.52 $97.18 (14%) | 🛒 Add to cart |
| 360 | $0.36
Best per pill | $151.36 $129.00 (15%) | 🛒 Add to cart |
Synonyms | |||
Voveran (diclofenac) is a potent nonsteroidal anti-inflammatory drug (NSAID) widely prescribed for the management of acute and chronic pain conditions accompanied by inflammation. As a cyclooxygenase (COX) inhibitor, it effectively reduces the production of prostaglandins, key mediators of pain, fever, and inflammatory responses. Its targeted action makes it a first-line therapeutic option for musculoskeletal disorders, postoperative pain, and dysmenorrhea. Available in multiple formulations—including oral tablets, topical gels, and injectable solutions—Voveran offers flexibility in treatment regimens tailored to individual patient needs and clinical scenarios. This medication requires a prescription and should be used under strict medical supervision to maximize efficacy and minimize potential risks.
Features
- Active ingredient: Diclofenac sodium or potassium
- Drug class: Nonsteroidal anti-inflammatory drug (NSAID)
- Available formulations: Oral tablets (including delayed-release and extended-release), topical gel, suppositories, injectable solution
- Mechanism of action: Reversible inhibition of cyclooxygenase (COX-1 and COX-2) enzymes
- Half-life: Approximately 2 hours
- Bioavailability: ~50-60% (oral); variable for topical formulations
Benefits
- Provides rapid and effective relief from moderate to severe pain
- Reduces inflammation and swelling in affected tissues
- Improves mobility and functional capacity in arthritis and injury patients
- Offers multiple administration routes for tailored therapeutic approaches
- Helps manage fever in adjunctive treatment protocols
- Supports shorter recovery times in postoperative and acute injury cases
Common use
Voveran is commonly prescribed for a range of inflammatory and painful conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal disorders such as sprains, strains, and tendinitis. It is also used for postoperative pain management, dental pain, and primary dysmenorrhea. Topical formulations are particularly beneficial for localized conditions like osteoarthritis of superficial joints, while oral and injectable forms address systemic inflammation and pain.
Dosage and direction
Dosage varies based on formulation, indication, and patient factors. For oral tablets in adults: 100-150 mg daily in divided doses (e.g., 50 mg two or three times daily). Extended-release tablets: 100 mg once daily. Topical gel: Apply 4g to affected area four times daily. Suppositories: 50-100 mg daily. Injectable solution: 75 mg by intramuscular injection, once or twice daily. Always take with food or milk to reduce gastrointestinal irritation. Do not crush or chew delayed-release tablets. For topical use, apply to intact skin; do not use with occlusive dressings unless directed.
Precautions
Use the lowest effective dose for the shortest duration possible. Monitor renal function in elderly patients and those with pre-existing renal impairment. Assess cardiovascular risk before long-term use. Avoid use in patients with history of GI bleeding or ulceration. Use caution in patients with hypertension, heart failure, or edema. Periodic liver function tests recommended during prolonged therapy. Discontinue at first sign of rash, mucosal lesions, or any allergic reaction. Not recommended during pregnancy, especially third trimester.
Contraindications
Hypersensitivity to diclofenac, aspirin, or other NSAIDs. History of asthma, urticaria, or allergic-type reactions after taking NSAIDs. Peri-operative pain in coronary artery bypass graft (CABG) surgery. Active gastrointestinal bleeding or ulceration. Severe heart failure (NYHA Class IV). Severe renal or hepatic impairment. Third trimester of pregnancy.
Possible side effect
Common: Nausea, dyspepsia, abdominal pain, diarrhea, headache, dizziness. Serious: GI ulceration/bleeding/perforation, cardiovascular thrombotic events, hypertension, heart failure, renal impairment, hepatotoxicity, severe skin reactions, anaphylaxis. Topical: Application site reactions (dryness, irritation, rash). Injectable: Pain at injection site.
Drug interaction
Significant interactions occur with: anticoagulants (increased bleeding risk), ACE inhibitors/ARBs (reduced antihypertensive effect), diuretics (reduced efficacy, renal risk), lithium (increased lithium levels), methotrexate (increased toxicity), cyclosporine (nephrotoxicity), other NSAIDs (additive toxicity), SSRIs/SNRIs (increased bleeding risk), corticosteroids (increased GI risk).
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. For once-daily formulations: if missed, take within 12 hours of missed dose; otherwise skip. For multiple daily doses: take if remembered within 4 hours of scheduled time.
Overdose
Symptoms may include nausea, vomiting, epigastric pain, GI bleeding, drowsiness, dizziness, tinnitus, seizures, respiratory depression, coma. Management is supportive: gastric lavage or activated charcoal if recent ingestion. Hemodialysis not effective due to high protein binding. Monitor and treat electrolyte imbalances, renal function, and GI effects. No specific antidote exists.
Storage
Store at room temperature (15-30°C). Protect from moisture and light. Keep oral formulations in original container. Topical gel: keep tube tightly closed. Suppositories: store below 25°C. Keep all formulations out of reach of children. Do not freeze. Do not use beyond expiration date.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. Individual response to therapy may vary. Proper diagnosis and supervision are essential for safe and effective use. The prescriber should be informed of all medical conditions and concurrent medications.
Reviews
Clinical studies and meta-analyses consistently demonstrate Voveran’s efficacy in pain reduction and inflammation control. A 2022 systematic review of 45 RCTs confirmed its superiority over placebo and non-inferiority to other NSAIDs in osteoarthritis pain management. Patient reports indicate rapid onset of action (within 30-60 minutes for oral forms) and significant functional improvement. Topical formulations receive particular praise for localized efficacy with minimal systemic exposure. Some reports note gastrointestinal discomfort as the most common reason for discontinuation. Overall, Voveran maintains a strong reputation among rheumatologists and pain specialists as a reliable option within the NSAID class.